

## Presentations

### *Scientific Meetings:*

“Designs and polydesigns for partially controlled studies”, **invited**, American Statistical Association, Annual Meeting (JSM), Minneapolis, August 2005.

“Partially Controlled Studies: the role of designs” **invited**, Western North American Region of the International Biometric Society, and Institute of Mathematical Statistics, Fairbanks, AL, June 2005.

“Designs and polydesigns for partially controlled studies”, **invited**, International Chinese Statistical Association, Washington DC, June 2005.

Gerontological Society of America 57th Annual Scientific Meeting, **invited** discussion, Washington DC, November 19-23, 2004.

“Principal Stratification for Partially Controlled Studies”, **invited**, International Society for Clinical Biostatistics, London, England, 2003.

“Evaluating the impact of the Baltimore Needle Exchange Program on HIV incidence using proximity to exchange sites among injection drug users”, (with Varadhan R, Brookmeyer, R, Strathdee, S, Vlahov, D, and Safaeian, M), American Public Health Association, Annual Meeting, San Francisco (2003).

“Polydesigns in studies of causal effects: motivation definition and implementation”, (with Li F and Varadhan R), American Statistical Association, Annual Meeting, San Francisco, CA, 2003.

“Principal Stratification for Partially Controlled Studies, and Application to Evaluating the Impact of the Baltimore Needle Exchange Program”, **invited**, International Biometrics Society (ENAR), Tampa, 2003, FL, 2003.

“Evaluating the Impact of the Baltimore Needle Exchange Program”, **invited**, American Mathematic Society, Joint Summer Research Conference, Mount Holyoke College, MA, 2002.

“The method of ‘principal causal effects’ for assessing surrogate endpoints: definition, estimation, and sensitivity analysis”, **invited**, International Biometrics Society (ENAR), Charlotte, NC, 2001.

“The role of potential confounders in causal inference with application to surrogate endpoints”, **invited**, American Statistical Association, Annual Meeting, Indianapolis, IN, 2000.

“Compliance-adjusted double-sampling designs for comparative research”, (with Baker, SG), **invited**, International Biometrics Society (ENAR), Annual Meeting, Chicago, IL, 2000.

“Bayesian analysis of the New York School Choice Scholarships program a randomized experiment with noncompliance and missing data”, based on peer reviewed paper, (with Barnard, J, Hill, J, and Rubin, DB), Case Studies in Bayesian Statistics 5, Carnegie Mellon University, Pittsburgh, PA, 1999.

“On the idiosyncrasy of estimating survival curves using double sampling in the presence of self-selected right censoring”, American Statistical Association, Annual Meeting, Baltimore, MD, 1999.

“Causal inference through potential outcomes”, (with Rubin, DB), **invited**, Nordic Network for Biostatistics Research, Karolinska Institute, Stockholm, Sweden, 1998.

“Causal inference through potential outcomes”, (with Rubin, DB), **invited**, European Meeting of Statisticians, Vilnius, Lithuania, 1998.

“The clustered encouragement design”, **invited**, American Statistical Association, Annual Meeting, Dallas, TX, 1998.

“Detecting indirect effects within the clustered encouragement design”, International Meeting on Bayesian Statistics, Valencia, Spain, 1998.

“Why intention-to-treat tests are generally anticonservative in the presence of both treatment noncompliance and outcome-nonresponse: revealing and handling this phenomenon”, **awarded**, The International Biometric Society (ENAR), Annual Meeting, Pittsburgh, PA, 1998.

“A new approach to the idiosyncratic problem of drug noncompliance with subsequent loss to follow-up”, American Statistical Association, Annual Meeting, Anaheim, CA, 1997.

*Invited Seminars:*

“Deviations from protocol: complication or window to more flexible designs ?” , NIH, March 22 2005.

“Biostatistical perspectives in translation of research: the links among ‘goal-design-analysis’”. Symposium on Issues in Successful Translation of Research: Applications to Research on Aging, Johns Hopkins University, Baltimore, MD, 2004.

“Evaluating the impact of the Baltimore Needle Exchange Program (NEP) on HIV incidence” Wharton School of Business, University of Pennsylvania, Philadelphia, PA, 2002.

Discussant on presentation by Marc Buyse, Biostatistics Grand Rounds, Johns Hopkins University, Baltimore, MD, 2000.

“The method of principal stratification in causal inference: addressing post-treatment variables. Examples on School Choice and surrogate endpoints.”, Seminar sponsored by NIMH and NIDA institutes, Department of Biostatistics, Johns Hopkins University, Baltimore, MD, 2000.

“Similarities between experiments with protocol deviations and observational studies: the use of potential confounders”, Merck Second Annual Seminar, West Point, PA, 2000.

“Clustered-encouragement-design and the central role of modeling”, Colloquium, Center for Statistical Sciences, Brown University, Providence, RI, 1999.

“On the idiosyncrasy of estimating survival curves using double sampling in the presence of self-selected right censoring”, Longitudinal Data Seminar, Department of Biostatistics, The Johns Hopkins University, Baltimore, MD, 1999.

“On the idiosyncrasy of estimating survival curves using double sampling in the presence of self-selected right censoring”, Applied Statistics Colloquium, Department of Mathematics, Boston University, Boston, MA, 1999.

“On the idiosyncrasy of estimating survival curves using double sampling in the presence of self-selected right censoring”, Colloquium, Department of Biostatistics, Harvard School of Public Health, Boston, MA, 1999.

“Addressing complications of intention-to-treat analysis in the presence of all-or-none treatment noncompliance and subsequent missing outcomes”, Colloquium, Department of Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, 1999.

“Addressing complications of intention-to-treat analysis in the presence of all-or-none treatment noncompliance and subsequent missing outcomes”, Colloquium, Department of Health Care Policy, Harvard Medical School, Boston, MA, 1999.

“Addressing complications of intention-to-treat analysis in the presence of all-or-none treatment noncompliance and subsequent missing outcomes”, Colloquium, Department of Biostatistics, Johns Hopkins University, Baltimore, MD, 1998.

“Addressing complications of intention-to-treat analysis in the presence of all-or-none treatment noncompliance and subsequent missing outcomes”, Colloquium, Department of Biostatistics, University of California at Los Angeles, Los Angeles, CA, 1998.

“Issues in intention-to-treat under nonresponse: an update”, Statistical Methods in Epidemiology, Harvard School of Public Health, Boston, MA, 1997.

“A new approach to the idiosyncratic problem of drug noncompliance with subsequent loss to follow-up”, Working Group on Methods on AIDS, Harvard School of Public Health, Boston, MA, 1997.